<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030870</url>
  </required_header>
  <id_info>
    <org_study_id>RenjiH-20201201</org_study_id>
    <nct_id>NCT05030870</nct_id>
  </id_info>
  <brief_title>Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients</brief_title>
  <acronym>CapnoGI</acronym>
  <official_title>Capnographic Monitoring Decrease the Incidence of Hypoxia of the Elderly Patients Undergoing Gastrointestinal Endoscopy Procedure: a Randomized Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoxia is the most common adverse event in gastrointestinal endoscopes sedated with propofol&#xD;
      and sufentanil, especially in elderly people. The aim of this randomized study was to&#xD;
      determine whether intervention based on additional capnographic monitoring reduces the&#xD;
      incidence of hypoxia in gastrointestinal endoscopes procedures for elderly patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of hypoxia</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average of 2 hours</time_frame>
    <description>(75% ≤ SpO2 &lt; 90% for &lt;60 s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of sub-clinical respiratory depression</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average about 2 hours</time_frame>
    <description>(90% ≤ SpO2 &lt; 95%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of severe hypoxia</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average about 2 hours</time_frame>
    <description>(SpO2 &lt; 75% or 75% ≤ SpO2 &lt; 90% for &gt;/=60 s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of capnography curve decreased by half or more than the baseline and even disappeared without hypoxia</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average about 2 hours</time_frame>
    <description>capnography curve decreased by half or more than the baseline and even disappeared, SpO2 &gt;90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of other adverse events</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected average about 2 hours</time_frame>
    <description>Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Hypoxia</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastric Polyp</condition>
  <condition>Colon Polyp</condition>
  <condition>Colon Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Capnographic monitoring group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, in addition to the standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients, the capnographic is also monitored. The capnographic data of the patients are available for additional noninvasive assessment of ventilation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard monitoring group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, standard monitoring including observation, pulse oxygen saturation, non-invasive blood pressure, electrocardiogram in selected patients. Capnographic data are not visible by closing the CO2 sampling line till the endoscopy end.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Capnography monitoring</intervention_name>
    <description>Standard monitoring and capnographic monitoring.</description>
    <arm_group_label>Capnographic monitoring group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard monitoring</intervention_name>
    <description>Standard monitoring but no capnographic monitoring</description>
    <arm_group_label>Capnographic monitoring group</arm_group_label>
    <arm_group_label>Standard monitoring group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  65 ≤ Age &lt;80&#xD;
&#xD;
          -  patients undergoing gastrointestinal endoscopes&#xD;
&#xD;
          -  patients signed informed consent form&#xD;
&#xD;
          -  ASA classification I-II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coagulation disorders or a tendency of nose bleeding&#xD;
&#xD;
          -  An episode/exacerbation of congestive heart failure (CHF) that requires a change in&#xD;
             medication, diet or hospitalization from any cause in the last 6 months&#xD;
&#xD;
          -  Severe aortic stenosis or mitral stenosis&#xD;
&#xD;
          -  Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG),&#xD;
             valve replacement surgery) in the last 6 months&#xD;
&#xD;
          -  Acute myocardial infarction in the last 6 months&#xD;
&#xD;
          -  Acute arrhythmia (including any tachycardia - or bradycardia) with the fluid of&#xD;
             hemodynamics instability&#xD;
&#xD;
          -  Diagnosed chronic obstructive pulmonary disease or current other acute or chronic lung&#xD;
             disease requiring supplemental chronic or intermittent oxygen therapy)&#xD;
&#xD;
          -  Pre-existing bradycardia (heart rate &lt; 50 / min), or hypoxia (SaO2&lt; 90 % )&#xD;
&#xD;
          -  Need supplemental oxygen because of pre-existing diseases&#xD;
&#xD;
          -  Emergency procedure or surgery&#xD;
&#xD;
          -  Multiple trauma&#xD;
&#xD;
          -  Upper respiratory tract infection&#xD;
&#xD;
          -  Allergy to propofol or tape and adhesives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diansan Su, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology Renji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diansan Su, Dr.</last_name>
    <phone>+862168383702</phone>
    <email>diansansu@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiuyue Lian, B.S.</last_name>
    <phone>+862168383702</phone>
    <email>l18724464815@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhenzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiaqiang Zhang, Dr.</last_name>
      <phone>13937121360</phone>
      <email>hnmzxh@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianbo Wu, Dr.</last_name>
      <phone>18560083793</phone>
      <email>jianbowu@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiuyue Lian, B.S.</last_name>
      <phone>+862168383702</phone>
      <email>l18724464815@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>diansan su</investigator_full_name>
    <investigator_title>Vice Chair of the Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Capnographic Monitoring</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Gastrointestinal endoscopy</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>Propofol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

